Stage IVC Squamous Cell Carcinoma of the Oropharynx Completed Phase 2 Trials for Sorafenib (DB00398)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0029839 (Stage IVC Squamous Cell Carcinoma of the Oropharynx) | Completed | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT00096512 | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Treatment | |
| NCT00939627 | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab | Treatment |